Cullen/Frost Bankers, Inc. Exelixis, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 2,148 shares of EXEL stock, worth $72,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,148Holding current value
$72,065% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
534Shares Held
245MCall Options Held
2.84MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.12 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$983 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$853 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$515 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$384 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.8B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...